BRPI0507654A - composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv - Google Patents

composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv

Info

Publication number
BRPI0507654A
BRPI0507654A BRPI0507654-4A BRPI0507654A BRPI0507654A BR PI0507654 A BRPI0507654 A BR PI0507654A BR PI0507654 A BRPI0507654 A BR PI0507654A BR PI0507654 A BRPI0507654 A BR PI0507654A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
fusion protein
benzodiazepine derivative
protein inhibitor
rsv fusion
Prior art date
Application number
BRPI0507654-4A
Other languages
English (en)
Inventor
Kenneth Powell
Richard Kelsey
Malcoml Carter
Dagmar Alber
Lara Wilson
Elisa Henderson
Phil Chambers
Debra Taylor
Stan Tyms
Verity Dowdell
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Publication of BRPI0507654A publication Critical patent/BRPI0507654A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM DERIVADO DE BENZODIAZEPINA E UM INIBIDOR DA PROTEìNA DE FUSãO DE RSV". A presente invenção refere-se a uma composição farmacêutica que compreende um diluente ou veículo farmaceuticamente aceitável e: (a) um inibidor da proteína de fusão de RSV; e (b) um derivado de benzodiazepina capaz de inibir replicação de RSV demostrou ser altamente ativo contra RSV.
BRPI0507654-4A 2004-03-19 2005-03-18 composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv BRPI0507654A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406282.4A GB0406282D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds
PCT/GB2005/001018 WO2005089769A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the rsv fusion protein

Publications (1)

Publication Number Publication Date
BRPI0507654A true BRPI0507654A (pt) 2007-07-10

Family

ID=32118068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507654-4A BRPI0507654A (pt) 2004-03-19 2005-03-18 composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv

Country Status (18)

Country Link
US (1) US8853204B2 (pt)
EP (1) EP1727550B1 (pt)
JP (1) JP4940128B2 (pt)
KR (2) KR20130042593A (pt)
CN (1) CN1933842A (pt)
AT (1) ATE437643T1 (pt)
AU (2) AU2005224157B2 (pt)
BR (1) BRPI0507654A (pt)
CA (1) CA2558112C (pt)
CY (1) CY1109523T1 (pt)
DE (1) DE602005015686D1 (pt)
DK (1) DK1727550T3 (pt)
ES (1) ES2327757T3 (pt)
GB (1) GB0406282D0 (pt)
PL (1) PL1727550T3 (pt)
PT (1) PT1727550E (pt)
RU (1) RU2388476C2 (pt)
WO (1) WO2005089769A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
MY197231A (en) * 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
CN108699077B (zh) 2016-01-15 2021-03-02 英安塔制药有限公司 作为rsv抑制剂的杂环化合物
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CA3077309A1 (en) * 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
NZ764647A (en) 2017-11-13 2025-12-19 Enanta Pharm Inc Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
KR102926658B1 (ko) 2019-03-18 2026-02-11 이난타 파마슈티칼스, 인코포레이티드 Rsv 억제제로서의 벤조디아제핀 유도체
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
GB202010409D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
IL305189A (en) 2021-02-26 2023-10-01 Enanta Pharm Inc Heterocyclic antiviral compounds
US12080039B2 (en) 2021-06-08 2024-09-03 Kyndryl, Inc. Contextual policy-based computer vision control
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
JP2001519806A (ja) * 1997-04-07 2001-10-23 アクシス ファーマシューティカルズ，インコーポレイティド セリンプロテアーゼ活性、特にトリプターゼ活性に関連する疾病を処理するための化合物及び組成物
AU741946B2 (en) * 1998-07-20 2001-12-13 Bristol-Myers Squibb Company Substituted benzimidazole antiviral agents
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
HUP0402535A2 (hu) * 2001-12-10 2005-04-28 Bristol-Myers Squibb Co. RSV fúzió inhibitor hatású imidazo-piridin-vegyület dihidroklorid-monohidrát sója és az ezt tartalmazó gyógyszerkészítmények
JP2004107494A (ja) * 2002-09-18 2004-04-08 National Institute For Materials Science 熱可塑性層状アルキルシロキサンとその製造方法
BR0314595A (pt) * 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds

Also Published As

Publication number Publication date
CA2558112C (en) 2014-07-29
HK1098372A1 (en) 2007-07-20
RU2388476C2 (ru) 2010-05-10
ATE437643T1 (de) 2009-08-15
DE602005015686D1 (de) 2009-09-10
JP4940128B2 (ja) 2012-05-30
EP1727550B1 (en) 2009-07-29
US20070142403A1 (en) 2007-06-21
KR20130042593A (ko) 2013-04-26
US8853204B2 (en) 2014-10-07
JP2007529489A (ja) 2007-10-25
KR101292431B1 (ko) 2013-07-31
EP1727550A1 (en) 2006-12-06
WO2005089769A1 (en) 2005-09-29
CY1109523T1 (el) 2014-08-13
AU2005224157A1 (en) 2005-09-29
AU2005224157B2 (en) 2009-05-28
PL1727550T3 (pl) 2010-01-29
ES2327757T3 (es) 2009-11-03
GB0406282D0 (en) 2004-04-21
CA2558112A1 (en) 2005-09-29
AU2009212826A1 (en) 2009-09-17
CN1933842A (zh) 2007-03-21
DK1727550T3 (da) 2009-10-19
KR20070009629A (ko) 2007-01-18
RU2006136880A (ru) 2008-04-27
PT1727550E (pt) 2009-08-28

Similar Documents

Publication Publication Date Title
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
SE0101932D0 (sv) Pharmaceutical combinations
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
WO2005117895A8 (en) Compositions comprising meloxicam
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
AU2001252419A1 (en) Thrombin inhibitors
BRPI0518891A2 (pt) composiÇço farmacÊutica àptica tàpica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.